We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
-22.77%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.72B
AUM Growth
-$1.36B
Cap. Flow
-$888M
Cap. Flow %
-51.56%
Top 10 Hldgs %
32.97%
Holding
299
New
73
Increased
48
Reduced
40
Closed
96

Top Buys

Rank Stock Value
1
GKOS icon
Glaukos
GKOS
+$37.8M
2
GH icon
Guardant Health
GH
+$19.9M
3
LUNG icon
Pulmonx
LUNG
+$15.2M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$13.5M
5
LYRA
LYRA THERAPEUTICS INC
LYRA
+$11.2M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$18M
2
CCCC icon
C4 Therapeutics
CCCC
+$15.2M
3
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$13.5M
4
ICUI icon
ICU Medical
ICUI
+$12.8M
5
CNVY
Convey Health Solutions Holdings, Inc.
CNVY
+$11.3M

Sector Composition

Rank Sector Weight
1 Healthcare 32.95%
2 Industrials 0.3%
3 Consumer Staples 0.27%
4 Materials 0.11%
5 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LIVN icon
26
LivaNova
LIVN
$4.33B
$16M 0.93%
256,848
-90,650
-26% -$6.42M
CLDX icon
27
CALL
Celldex Therapeutics
CLDX
$3.48B
$16M 0.93%
594,800
+198,200
+50% +$5.76M
RVTY icon
28
PUT
Revvity
RVTY
$12.9B
$15.6M 0.91%
+110,000
New +$16.5M
PEN icon
29
PUT
Penumbra
PEN
$12.9B
$15.6M 0.9%
+125,000
New +$19.8M
BMY icon
30
PUT
Bristol-Myers Squibb
BMY
$130B
$15.4M 0.89%
+200,000
New +$15.2M
HQY icon
31
CALL
HealthEquity
HQY
$8.83B
$15.3M 0.89%
250,000
+70,000
+39% +$4.48M
PRVA icon
32
CALL
Privia Health
PRVA
$2.81B
$15.3M 0.89%
525,000
+225,000
+75% +$5.72M
SRPT icon
33
CALL
Sarepta Therapeutics
SRPT
$1.92B
$15M 0.87%
200,000
– –
LYRA
34
DELISTED
LYRA THERAPEUTICS INC
LYRA
$14.6M 0.85%
51,524
+41,113
+395% +$11.2M
UTHR icon
35
United Therapeutics
UTHR
$22.1B
$14.3M 0.83%
60,650
+44,089
+266% +$8.96M
TAP icon
36
PUT
Molson Coors Class B
TAP
$7.83B
$14.1M 0.82%
258,300
+40,000
+18% +$2.15M
LNTH icon
37
Lantheus
LNTH
$6.57B
$14M 0.81%
212,238
-10,000
-4% -$630K
ALNY icon
38
Alnylam Pharmaceuticals
ALNY
$29.6B
$13.9M 0.81%
+95,240
New +$13.5M
STAA icon
39
STAAR Surgical
STAA
$1.24B
$13.9M 0.81%
195,810
-264
-0.1% -$17K
ALGN icon
40
PUT
Align Technology
ALGN
$12.3B
$13M 0.76%
+55,000
New +$16.9M
BNTX icon
41
CALL
BioNTech
BNTX
$23.3B
$11.9M 0.69%
+80,000
New +$12.2M
TXG icon
42
PUT
10x Genomics
TXG
$7.62B
$11.3M 0.66%
250,000
-34,400
-12% -$1.78M
ILMN icon
43
PUT
Illumina
ILMN
$29.1B
$11.1M 0.64%
+61,680
New +$15.8M
AZN icon
44
AstraZeneca
AZN
$246B
$10.8M 0.62%
81,414
+66,414
+443% +$8.71M
MEDP icon
45
PUT
Medpace
MEDP
$16.9B
$10.5M 0.61%
70,000
+40,000
+133% +$5.79M
COO icon
46
Cooper Companies
COO
$15B
$10.2M 0.59%
130,000
+78,000
+150% +$6.9M
NTLA icon
47
PUT
Intellia Therapeutics
NTLA
$1.68B
$10.1M 0.59%
+194,800
New +$9.89M
CGC
48
PUT
Canopy Growth
CGC
$422M
$9.97M 0.58%
+350,000
New +$18.2M
SLGC
49
DELISTED
SomaLogic, Inc. Class A Common Stock
SLGC
$9.6M 0.56%
2,123,120
-352,695
-14% -$2.1M
TNDM icon
50
PUT
Tandem Diabetes Care
TNDM
$1.63B
$9.47M 0.55%
+160,000
New +$13.1M
1
2
3 4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q2 2022 Portfolio in Review

As of Q2 2022, Pura Vida Investments held 299 positions worth $1.72B, down 44% from $3.08B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Pura Vida Investments withdrew a net $888M in Q2 2022, closing 96 positions and reducing 40 holdings. Its most notable exit was C4 Therapeutics, an estimated $15.2M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 33% of assets, up from 24% a quarter earlier, followed by Industrials and Consumer Staples.

Against the trend, Pura Vida Investments opened a new position in Glaukos worth $36.2M.

  • Pura Vida Investments's largest Q2 2022 buy was Glaukos: 796,600 shares worth $36.2M.
  • Pura Vida Investments added most to Guardant Health in Q2 2022, an estimated $19.9M increase.
  • Pura Vida Investments's biggest Q2 2022 reduction was Vertex Pharmaceuticals, cutting an estimated $18M.
  • Pura Vida Investments fully exited C4 Therapeutics in Q2 2022, selling an estimated $15.2M.
  • Pura Vida Investments's ten largest holdings make up 33% of its $1.72B portfolio in Q2 2022.
  • Pura Vida Investments opened 73 new positions and closed 96 in Q2 2022.
  • Pura Vida Investments's portfolio value fell 44% quarter-over-quarter to $1.72B.

Based on Pura Vida Investments's 13F filing for Q2 2022, filed 15 Aug 2022.